Mangyeong Lee1,2, Danbee Kang2,3, Sooyeon Kim2,3, Jihyun Lim2, Junghee Yoon1,3,4, Youngha Kim2, Sungkeun Shim1,2, Eunji Kang2,5, Jin Seok Ahn6, Juhee Cho1,2,3,7,8, Soo-Yong Shin9,10, Dongryul Oh11. 1. Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, South Korea. 2. Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 3. Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea. 4. Patient-Centered Outcomes Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 5. Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, South Korea. 6. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 7. Cancer Education Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 8. Department of Health, Behavior and Society and Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 9. Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, South Korea. sy.shin@skku.edu. 10. Center for Research Resource Standardization, Samsung Medical Center, Seoul, South Korea. sy.shin@skku.edu. 11. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. dongryul.oh@samsung.com.
Abstract
PURPOSE: This study aims to identify factors associated with the adoption and compliance of electronic patient-reported outcome measure (ePROM) use among cancer patients in a real-world setting. METHODS: This prospective cohort study was conducted at the Samsung Medical Center in Seoul, Korea, from September 2018 to January 2019. Cancer patients aged 18 years or older who owned smartphones and who were receiving chemotherapy or radiation therapy were eligible for this study. Patients were asked to use the app to report their symptoms every 7 days for a total of 21 days (3 weeks). Logistic regression was performed to identify the factors associated with the adoption and compliance. RESULTS: Among 580 patients, 417 (71.9%) adopted the ePROM app and 159 (27.4%) out of 417 had good compliance. Patients who had greater expectations regarding the ease of use (adjusted odds ratio [aOR] 2.67, 95% CI: 1.28-5.57) and usefulness (aOR 1.69, 95% CI: 1.05-2.72) of the ePROM app were more likely to adopt the app than those who did not. Patients who had greater satisfaction with usefulness (aOR 1.89, 95% CI 1.10-3.25) were more likely to comply with using the app, but satisfaction with ease of use was not related to the compliance. CONCLUSION: While expectation regarding the ease of use and usefulness of the ePROM app was associated with the adoption of the app, satisfaction with ease of use was not related to compliance with the ePROM app. Satisfaction with usefulness was associated with the compliance of ePROM app use.
PURPOSE: This study aims to identify factors associated with the adoption and compliance of electronic patient-reported outcome measure (ePROM) use among cancer patients in a real-world setting. METHODS: This prospective cohort study was conducted at the Samsung Medical Center in Seoul, Korea, from September 2018 to January 2019. Cancer patients aged 18 years or older who owned smartphones and who were receiving chemotherapy or radiation therapy were eligible for this study. Patients were asked to use the app to report their symptoms every 7 days for a total of 21 days (3 weeks). Logistic regression was performed to identify the factors associated with the adoption and compliance. RESULTS: Among 580 patients, 417 (71.9%) adopted the ePROM app and 159 (27.4%) out of 417 had good compliance. Patients who had greater expectations regarding the ease of use (adjusted odds ratio [aOR] 2.67, 95% CI: 1.28-5.57) and usefulness (aOR 1.69, 95% CI: 1.05-2.72) of the ePROM app were more likely to adopt the app than those who did not. Patients who had greater satisfaction with usefulness (aOR 1.89, 95% CI 1.10-3.25) were more likely to comply with using the app, but satisfaction with ease of use was not related to the compliance. CONCLUSION: While expectation regarding the ease of use and usefulness of the ePROM app was associated with the adoption of the app, satisfaction with ease of use was not related to compliance with the ePROM app. Satisfaction with usefulness was associated with the compliance of ePROM app use.
Authors: Qiuling Shi; Tenbroeck G Smith; Jared D Michonski; Kevin D Stein; Chiewkwei Kaw; Charles S Cleeland Journal: Cancer Date: 2011-04-14 Impact factor: 6.860
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Roxanne E Jensen; Claire F Snyder; Amy P Abernethy; Ethan Basch; Arnold L Potosky; Aaron C Roberts; Deena R Loeffler; Bryce B Reeve Journal: J Oncol Pract Date: 2013-12-03 Impact factor: 3.840
Authors: Martin W Schoen; Ethan Basch; Lori L Hudson; Arlene E Chung; Tito R Mendoza; Sandra A Mitchell; Diane St Germain; Paul Baumgartner; Laura Sit; Lauren J Rogak; Marwan Shouery; Eve Shalley; Bryce B Reeve; Maria R Fawzy; Nrupen A Bhavsar; Charles Cleeland; Deborah Schrag; Amylou C Dueck; Amy P Abernethy Journal: JMIR Hum Factors Date: 2018-07-16